Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 30

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 30
---
 pursuant to the Purchase Agreement will be purchased at a discounted
price.

For example, we may effect
sales to the Selling Shareholder pursuant to a Fixed Purchase Notice at a purchase price equal to the lesser of 95% of (i) the VWAP of the Depositary Shares for the five trading days immediately preceding the applicable Purchase Date for such Fixed Purchase and (ii) the lowest sale price of a Depositary Share on the trading day preceding applicable Purchase Date. See “The Committed Equity Financing” for more information.

As a result of this pricing
structure, the Selling Shareholder may sell the shares they receive immediately after receipt of such shares, which could cause the price
of our Depositary Shares to decrease.

Investors who buy Depositary Shares from the Selling Shareholder at different times will likely pay different prices.

Pursuant
to the Purchase Agreement, we have discretion (subject to the restrictions and satisfaction of the conditions in the Purchase Agreement)
to vary the timing, price and number of Depositary Shares we sell to the Selling Shareholder. If and when we elect to sell Depositary
Shares to the Selling Shareholder pursuant to the Purchase Agreement, after the Selling Shareholder has acquired such shares, the Selling
Shareholder may resell all, some or none of such shares at any time or from time to time in its sole discretion and at different prices.
As a result, investors who purchase shares from the Selling Shareholder in this offering at different times will likely pay different
prices for those shares, and so may experience different levels of dilution and in some cases substantial dilution and different outcomes
in their investment results. Investors may experience a decline in the value of the shares they purchase from the Selling Shareholder
in this offering as a result of future sales made by us to the Selling Shareholder at prices lower than the prices such investors paid
for their shares in this offering. In addition, if we sell a substantial number of shares to the Selling Shareholder under the Purchase
Agreement, or if investors expect that we will do so, the actual sales of shares or the mere existence of our arrangements with the Selling
Shareholder may make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that
we might otherwise wish to effect such sales.

We may use proceeds from sales of ourDepositary Shares made pursuant to the Purchase Agreement in ways with which you may not agree or in ways which may not yield a significant return.

We will have broad